Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancerMaria Vittoria Dieci, Valentina Guarneri, Antonella Ferro et al.|Annals of Oncology|2019Cited by 96
Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trialValentina Guarneri, PierFranco Conte, Maria Vittoria Dieci et al.|European Journal of Cancer|2021Cited by 42
Tumor-Infiltrating Lymphocytes and Survival Outcomes in Early <i>ERBB2</i>-Positive Breast CancerMaria Vittoria Dieci, Valentina Guarneri, Giancarlo Bisagni et al.|JAMA Oncology|2025Cited by 17
Survival analysis of the prospective randomized Cher-Lob study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer (BC).Valentina Guarneri, PierFranco Conte, Maria Vittoria Dieci et al.|Journal of Clinical Oncology|2020Cited by 3
Survival analysis of the prospective randomized Cher-Lob study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancerValentina Guarneri, PierFranco Conte, Maria Vittoria Dieci et al.|IRIS UNIMORE (University of Modena and Reggio Emilia)|2020Cited by 0